君实生物（688180.SH/01877.HK）今日盘中大涨5.33%，引起市场广泛关注。这一强劲涨势主要得益于公司最新发布的2024年年度报告中令人鼓舞的财务数据。
根据公司公告，君实生物2024年实现营业收入19.48亿元，同比增长29.67%。更值得注意的是，公司净亏损大幅收窄，归属于母公司股东的净亏损为12.81亿元，同比减少43.90%。这一业绩改善主要源于公司商业化药品销售收入的显著增长，以及公司积极实施的"提质增效重回报"行动计划。
君实生物的主打产品——国产PD-1单抗药物特瑞普利单抗（商品名：拓益）表现尤为亮眼。2024年，拓益在国内市场的销售收入达到15.01亿元，同比增长约66%。这一增长与拓益在2024年获批4项新适应症密切相关，目前该药物已拥有11项适应症。此外，公司近期还宣布特瑞普利单抗联合贝伐珠单抗用于治疗肝细胞癌的新适应症获批，进一步扩大了产品的应用范围。投资者对公司产品线的扩展和未来增长潜力表示乐观，推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.